MarketCapExport financials
Corvus Pharmaceuticals (CRVS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Corvus Pharmaceuticals Balance Sheet 2025-2011 | CRVS
Brief overview of Corvus Pharmaceuticals's financial position
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
The asset base decreased -35%, from $109.5 million to $71.1 million. Resources became smaller over the five periods.
Funding shifted toward liabilities: they gained -19.4%, compared with -35% for assets.
Equity funds 86.1% of assets versus 88.8% initially. This creates a conservative balance sheet structure.
Cash exceeds interest-bearing debt, producing net debt of -$3.6 million. The balance sheet therefore carries a net cash position.
Cash equals 6.4% of the balance sheet, compared with 58% five periods ago. This is the readily available cushion.
Retained earnings remain negative at -$412.3 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall assessment
Corvus Pharmaceuticals's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Corvus Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-3.64 M | -7.62 M | - | -10.6 M | -59.8 M | - | -1.97 M | -39.2 M | -45.1 M | -5.05 M | -4.1 M | -9.92 M | - | - | - |
Long Term Debt |
534 K | 937 K | - | 1.37 M | 2.6 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
403 K | 185 K | 1.37 M | 1.23 M | 1.05 M | 1.08 M | 878 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 2.31 M | 869 K | 971 K | 1.4 M | 126 M | 10 M | - | - | - |
Total Current Liabilities |
9.38 M | 35.4 M | 6.87 M | 10.8 M | 9.69 M | 12.1 M | 10.2 M | 7.03 M | 8.97 M | 5.94 M | - | - | - | - | - |
Total Liabilities |
9.91 M | 36.3 M | 6.87 M | 12.1 M | 12.3 M | 13.4 M | 12.5 M | 7.9 M | 9.94 M | 7.35 M | 130 M | 12.7 M | - | - | - |
Retained Earnings |
-412 M | -397 M | -335 M | -308 M | -266 M | -223 M | -217 M | -170 M | -124 M | -67.9 M | -31.5 M | -161 K | - | - | - |
Total Assets |
71.1 M | 68.9 M | 45.6 M | 68.2 M | 109 M | 85.5 M | 83.6 M | 118 M | 94.8 M | 140 M | 98.5 M | 12.5 M | - | - | - |
Cash and Cash Equivalents |
4.58 M | 8.74 M | 12.6 M | 13.2 M | 63.5 M | 16.5 M | 5.15 M | 39.2 M | 45.1 M | 5.05 M | 4.1 M | 12.5 M | - | - | - |
Book Value |
61.2 M | 32.6 M | 38.7 M | 56.1 M | 97.2 M | 72.1 M | 71.1 M | 110 M | 84.8 M | 133 M | -31.1 M | -159 K | - | - | - |
Total Shareholders Equity |
61.2 M | 32.6 M | 38.7 M | 56.1 M | 97.2 M | 72.1 M | 71.1 M | 110 M | 84.8 M | 133 M | -31.1 M | -159 K | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Corvus Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
274 K | 406 K | 632 K | 728 K | 834 K | 937 K | - | - | - | - | 354 K | 700 K | 1.04 M | 1.37 M | 1.69 M | 2 M | 2.3 M | 2.6 M | 2.87 M | 631 K | 935 K | 1.23 M | 1.23 M | 1.23 M | 1.23 M | 2.31 M | 2.31 M | 2.31 M | 2.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
13.9 M | 12.5 M | 8.71 M | 9.23 M | 10.1 M | 36.3 M | 46.4 M | 13.3 M | 6.72 M | 6.87 M | 7.65 M | 8.56 M | 9.33 M | 12.1 M | 15.7 M | 12.2 M | 11.6 M | 12.3 M | 14.2 M | 13 M | 14.9 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 9.94 M | 9.94 M | 9.94 M | 9.94 M | 7.35 M | 7.35 M | 7.35 M | 7.35 M | 3.78 M | 3.78 M | 3.78 M | 3.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-444 M | -426 M | -400 M | -390 M | -382 M | -397 M | -385 M | -345 M | -340 M | -335 M | -328 M | -322 M | -316 M | -308 M | -298 M | -283 M | -275 M | -266 M | -257 M | -246 M | -235 M | -223 M | -223 M | -223 M | -223 M | -217 M | -217 M | -217 M | -217 M | -170 M | -170 M | -170 M | -170 M | -124 M | -124 M | -124 M | -124 M | -67.9 M | -67.9 M | -67.9 M | -67.9 M | -31.5 M | -31.5 M | -31.5 M | -31.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
239 M | 253 M | 80.5 M | 89.5 M | 59.4 M | 68.9 M | 58.8 M | 64.6 M | 40.1 M | 45.6 M | 51.9 M | 58 M | 58.2 M | 68.2 M | 80.3 M | 92.5 M | 101 M | 109 M | 119 M | 109 M | 109 M | 85.5 M | 85.5 M | 85.5 M | 85.5 M | 83.6 M | 83.6 M | 83.6 M | 83.6 M | 118 M | 118 M | 118 M | 118 M | 94.8 M | 94.8 M | 94.8 M | 94.8 M | 140 M | 140 M | 140 M | 140 M | 98.5 M | 98.5 M | 98.5 M | 98.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
18.9 M | 40.1 M | 2.87 M | 14.7 M | 5 M | 8.74 M | 4.68 M | 14.8 M | 7.46 M | 12.6 M | 20.1 M | 7.66 M | 9.65 M | 13.2 M | 24.6 M | 28.5 M | 31.5 M | 63.5 M | 72.3 M | 58.9 M | 45.1 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 5.15 M | 5.15 M | 5.15 M | 5.15 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 5.05 M | 5.05 M | 5.05 M | 5.05 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
225 M | 241 M | 71.8 M | 80.2 M | 49.3 M | 32.6 M | 12.4 M | 51.2 M | 33.4 M | 38.7 M | 44.3 M | 49.5 M | 48.9 M | 56.1 M | 64.7 M | 80.4 M | 89.7 M | 97.2 M | 105 M | 96.4 M | 94.4 M | 72.1 M | 72.1 M | 72.1 M | 72.1 M | 71.1 M | 71.1 M | 71.1 M | 71.1 M | 110 M | 110 M | 110 M | 110 M | 84.8 M | 84.8 M | 84.8 M | 84.8 M | 133 M | 133 M | 133 M | 133 M | 94.7 M | 94.7 M | 94.7 M | 94.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
225 M | 241 M | 71.8 M | 80.2 M | 49.3 M | 32.6 M | 12.4 M | 51.2 M | 33.4 M | 38.7 M | 44.3 M | 49.5 M | 48.9 M | 56.1 M | 64.7 M | 80.4 M | 89.7 M | 97.2 M | 105 M | 96.4 M | 94.4 M | 72.1 M | 72.1 M | 72.1 M | 72.1 M | 71.1 M | 71.1 M | 71.1 M | 71.1 M | 110 M | 110 M | 110 M | 110 M | 84.8 M | 84.8 M | 84.8 M | 84.8 M | 133 M | 133 M | 133 M | 133 M | -31.1 M | -31.1 M | -31.1 M | -31.1 M | -159 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Corvus Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
